ReviewBrain : a journal of neurology2019
Targeting the complement system in bacterial meningitis.
Review in Brain : a journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- Maternal Infection Impairs Motor Coordination in an Experimental Meningitis Rat Model Through Altered MMP-2/3/9 Activity, H3K4 Trimethylation, andInternational journal of molecular sciences · 2026Article
- Complement and inflammasome crosstalk in chronic inflammation.Frontiers in immunology · 2026Review
- Review
- Complement Cascades and Brain Disorders.Biomolecules · 2025Review
- Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.Immune network · 2025Review
- Therapeutic strategies targeting complement in myasthenia gravis patients.Journal of neurology · 2025Review
- Delayed cerebral vasculopathy following pneumococcal meningitis: a case report.Oxford medical case reports · 2025Article
- Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications.PloS one · 2025Article
- Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis.Journal of biomedical science · 2024Review
- Adjunctive treatments for pneumococcal meningitis: a systematic review of experimental animal models.Brain communications · 2024Review
- Complement Factor I Gene Variant as a Treatable Cause of Recurrent Aseptic Neutrophilic Meningitis: A Case Report.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis.Open forum infectious diseases · 2023Article
- Human Listeriosis.Clinical microbiology reviews · 2023Review
- Clinical application value of metagenomic next-generation sequencing in the diagnosis of central nervous system infections.Frontiers in bioengineering and biotechnology · 2023Article
- Ferroptosis and mitochondrial dysfunction in acute central nervous system injury.Frontiers in cellular neuroscience · 2023Review
- Melatonin inhibits Gram-negative pathogens by targeting citrate synthase.Science China. Life sciences · 2022Article
- Pneumococcal Meningitis in Adults: A Prospective Nationwide Cohort Study Over a 20-year Period.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Long non-coding RNA lncC11orf54-1 modulates neuroinflammatory responses by activating NF-κB signaling during meningitic Escherichia coli infection.Molecular brain · 2022Article
- CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the complement system in upregulating and maintaining the inflammatory response in bacterial meningitis. Genetic variation studies, complement level measurements in blood and CSF, and experimental work have together led to the identification of anaphylatoxin C5a as a promising treatment target in bacterial meningitis. In animals and patients with pneumococcal meningitis, the accumulation of neutrophils in the CSF was mainly driven by C5-derived chemotactic activity and correlated positively with disease severity and outcome. In murine pneumococcal meningitis, adjunctive treatment with C5 antibodies prevented brain damage and death. Several recently developed therapeutics target C5 conversion, C5a, or its receptor C5aR. Caution is warranted because treatment with C5 antibodies such as eculizumab also inhibits the formation of the membrane attack complex, which may result in decreased meningococcal killing and increased meningococcal disease susceptibility. The use of C5a or C5aR antagonists to specifically target the harmful anaphylatoxins-induced effects, therefore, are most promising and present opportunities for a phase 2 clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.